Corient Private Wealth LP Makes New $4.38 Million Investment in IQVIA Holdings Inc. $IQV

Corient Private Wealth LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, Holdings Channel reports. The firm acquired 22,663 shares of the medical research company’s stock, valued at approximately $4,379,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. acquired a new position in IQVIA during the 2nd quarter valued at $2,811,292,000. Boston Partners bought a new position in shares of IQVIA during the 3rd quarter worth about $676,698,000. Norges Bank acquired a new position in shares of IQVIA during the fourth quarter valued at about $497,445,000. Victory Capital Management Inc. lifted its stake in shares of IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after buying an additional 1,614,063 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in IQVIA during the second quarter worth about $240,911,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a report on Thursday, July 9th. Robert W. Baird lifted their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. TD Cowen upped their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. William Blair raised IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, BMO Capital Markets lifted their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Down 0.2%

NYSE IQV opened at $261.29 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $265.25. The company has a market capitalization of $43.01 billion, a price-to-earnings ratio of 32.42, a PEG ratio of 2.24 and a beta of 1.18. The stock’s 50 day moving average is $224.00 and its two-hundred day moving average is $190.15. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has authorized a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 in the last ninety days. Insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.